Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Stocks · News reference
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Investment firm H.C. Wainwright has initiated coverage on Savara Inc. with a Buy rating and a price target of $10.00 per share.
Savara Inc. granted equity-based inducement awards to seven new employees on November 10, 2026.
Savara Inc. has released new data demonstrating the treatment effects of its molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP) who exhibit mild diffusion impairment.
JP Morgan analyst Caroline Pocher initiates coverage on Savara (NASDAQ:SVRA) with a Overweight rating and announces Price Target of $12.
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.